drugset
drugset / Trial / NCT05494723

Safety and Efficacy of YB-1113 in Treatment of POI

NCT05494723 ↗

Phase 1 Not yet recruiting 6 enrolled Bright Cell, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

This phase 1 study is to evaluate the safety and tolerability of YB-1113 administered via intravenous (IV) infusion in the treatment of premature ovarian insufficiency (POI).

Timeline

Start
2026-12-09
Primary completion
2028-01-09
Completion
2028-04-09

Drugs

EvaluationDrugModalityDoseRoute
Subject human umbilical cord mesenchymal stem cells Cell therapy — Intravenous

Indications

No indication recorded.